ARZNEIMITTEL MIT CYTOSTATISCHER WIRKUNG SOWIE VERWENDUNG VON MEHRFACH MIT GLYCIDYLGRUPPEN SUBSTITUIERTEN N-HETEROCYCLISCHEN RINGVERBINDUNGEN IN PHARMAZEUTISCHEN ZUBEREITUNGEN.

摘要

New medicinal preparations with cytostatic activity contain N-heterocycles the ring system of which contain at least two glycidyl-substd. N-atoms in amide and/or imide form, the glycidyl residues of which corresp. to the formula (I) (where R is H or 1-4C alkyl). Specifically disclaimed are preparations contg. triglycidyl-isocyanurate and diglycidyl-isocyanates the third N-atom of which is substd. by a hydrocarbon residue. Preferred glycidyl-substd. N-heterocycles include 1,3-bis-glycidyl -2-benzimidazolinone derivs., di, tri- or tetra-glycidyl- perhydroimidazo (4,5-d) imidazole-2,5-dione derivs., N,N'-diglycidyl-hydantoin derivs., 1,3-diglycidyl-s-triazine-2,4, 6-trione derivs.; N,N'-diglycidyluracil derivs., 2,4-diglycidyl-1,2, 4-triazole-3,5-dione derivs. and diglycidyl-1,2,4-triazolidine-3, 5-dione derivs. Diglycidyl N-heterocycles of the type specified above have cytostatic activity. They are suitable for use in the treatment of various leukaemias as well as malignant neoplasms such as lung carcinoma, colon carcinoma, melanoma, ependynaoblastoma and sarcoma.